Smart Immune
Paris
About Smart Immune
Smart Immune is a clinical-stage biotechnology company focused on developing the next generation of hematopoietic stem cell-based biotherapies to change the prognosis and life quality of patients with devastating diseases. The company's first cell therapy program is based on T cell progenitors or ProTcellsTM (CD7+/CD34-; CD5- cells) curative power to enable a short, polyclonal, and safe post-transplantation immune recovery. This program be completed by integrative developments from targeted conditioning to gene therapy and genome editing enabling clinicians to access new-generation treatments for a wide variety of inherited blood disorders and blood cancers.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $27.3M
- Last round: Grant (Apr 2023)
- Website: smart-immune.com
- Phone: 0033680581505
Industries & Categories
Biotechnology, Health Care, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/smart-immune-81407 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.